Stock Screener App

Frei -

Installieren

4.815

5.76% 0.215

Lexeo Therapeutics Inc (LXEO)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten

LXEOLexeo Therapeutics Inc Dividends - Finviz

Have Insiders Sold Lexeo Therapeutics Shares Recently? - simplywall.st

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance

Lexeo Therapeutics CMO sells $98,592 in shares - Investing.com

Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com - Investing.com Australia

Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com

Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com - Investing.com India

Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com - Investing.com India

RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan

Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale - Stock Titan

Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes - Stock Titan

Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan

Form 144 Lexeo Therapeutics For: 1 July By Investing.com - Investing.com UK

LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity - Stock Titan

[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan

LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares - Stock Titan

5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey

Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa

Lexeo Shareholders Reelect Directors, Ratify KPMG Auditor - TipRanks

Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor - Stock Titan

Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan

Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70 - Stock Titan

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 - Stock Titan

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike - Stock Titan

Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70 - Stock Titan

Lexeo Therapeutics, Inc. Actuals & Estimates (NASDAQ:LXEO) - TradingView

LXEO Forecast — Price Target — Prediction for 2027 - TradingView

Price to sales forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView

Price to book forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView

Price to earnings forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView

LEXEO THERAPEUTICS INC (LXEO) Stock Chart - ChartMill

Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan - Moomoo

LXEO Maintained by JP Morgan -- Price Target Lowered to $9.00 - GuruFocus

Lexeo Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo

J.P. Morgan Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $9 - Moomoo

Lexeo Therapeutics’s LX2006 Has A Viable Regulatory Pathway And Timeline (NASDAQ:LXEO) - Seeking Alpha

Lexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy Designation - MSN

LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill

Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Insiders In Lexeo Therapeutics Left Out From 21% Price Rise After Disposing Stock - 富途牛牛

Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Lexeo Therapeutics Inc (LXEO) Institutional Confidence - TradingKey

Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey

Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Lexeo publishes phase I/II data for gene therapy LX2006 By Investing.com - Investing.com South Africa

Lexeo publishes phase I/II data for gene therapy LX2006 - Investing.com

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia - GlobeNewswire

Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Why is Lexeo Therapeutics stock gaining Monday? - MSN

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst CallSlideshow (NASDAQ:LXEO) 2026-06-15 - Seeking Alpha

LXEO: Pivotal LX2006 trial in FA finalized, aiming for accelerated approval with strong early data - TradingView

Why Is Lexeo Therapeutics Stock Gaining Monday? - Benzinga

Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy - Moomoo

Lexeo Therapeutics (LXEO) Advances Gene Therapy Trial for Friedr - GuruFocus

Lexeo finalizes pivotal trial design for gene therapy LX2006 By Investing.com - Investing.com South Africa

LXEO: Pivotal LX2006 trial in FA to start, targeting LVMI reduction with accelerated approval path - TradingView

Lexeo finalizes pivotal trial design for gene therapy LX2006 - Investing.com UK

2 Stocks To Watch Today Following Clinical Trial Updates - RTTNews

INSM

$112.77

1.03%

RPRX

$57.70

1.42%

ROIV

$36.25

2.52%

MRNA

$79.35

2.69%

ONC

$306.35

0.72%

RVMD

$190.47

0.31%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters